Genotype-phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia.
Journal
Current opinion in lipidology
ISSN: 1473-6535
Titre abrégé: Curr Opin Lipidol
Pays: England
ID NLM: 9010000
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
medline:
2
11
2023
pubmed:
9
2
2023
entrez:
8
2
2023
Statut:
ppublish
Résumé
Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease (CVD). Both the heterozygous form and the very severe homozygous form can be diagnosed by genetic testing and by clinical criteria. Genetic testing can discern FH in a form caused by complete absence of the LDL-receptors, the negative variant and a form leading to reduced activity of the LDL receptors, the defective variant. The aim of this study is to provide more insight in the genotype-phenotype correlation in children and adolescents diagnosed with heterozygous FH (HeFH) and with homozygous FH (HoFH), specifically in relation to the clinical and therapeutic consequences of the negative and defective variant of FH. Data of 5904 children with a tentative diagnosis of FH referred to our center for genetic testing were collected. A lipid-profile was present in 3494 children, who became the study cohort. In this large cohort of children, which includes 2714 HeFH and 41 HoFH patients, it is shown that receptor negative variants are associated with significant higher LDL-C levels in HeFH patients than receptor defective variants (6.0 versus 4.9 mmol/L; p < 0.001). A negative/negative variant is associated with a significant higher LDL-C level jn HoFH patients than a negative/defective variant, which in itself has a higher LDL-C level than a defective/defective variant. Significantly more premature CVD is present in close relatives of children with HeFH with negative variants compared to close relatives of HeFH children with defective variants (75% vs 59%; p < 0.001). Performing genetic testing and identifying the type of underlying genetic variant is of added value in order to distinguish between pediatric patients with higher risks of premature CVD and to identify those that will benefit most from new types of lipid-lowering therapies. Since in children the phenotype of FH is less affected by environmental factors, the study substantiates the genotype-phenotype correlation in this large pediatric population.
Sections du résumé
BACKGROUND
Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease (CVD). Both the heterozygous form and the very severe homozygous form can be diagnosed by genetic testing and by clinical criteria. Genetic testing can discern FH in a form caused by complete absence of the LDL-receptors, the negative variant and a form leading to reduced activity of the LDL receptors, the defective variant. The aim of this study is to provide more insight in the genotype-phenotype correlation in children and adolescents diagnosed with heterozygous FH (HeFH) and with homozygous FH (HoFH), specifically in relation to the clinical and therapeutic consequences of the negative and defective variant of FH.
METHODS AND RESULTS
Data of 5904 children with a tentative diagnosis of FH referred to our center for genetic testing were collected. A lipid-profile was present in 3494 children, who became the study cohort. In this large cohort of children, which includes 2714 HeFH and 41 HoFH patients, it is shown that receptor negative variants are associated with significant higher LDL-C levels in HeFH patients than receptor defective variants (6.0 versus 4.9 mmol/L; p < 0.001). A negative/negative variant is associated with a significant higher LDL-C level jn HoFH patients than a negative/defective variant, which in itself has a higher LDL-C level than a defective/defective variant. Significantly more premature CVD is present in close relatives of children with HeFH with negative variants compared to close relatives of HeFH children with defective variants (75% vs 59%; p < 0.001).
CONCLUSIONS
Performing genetic testing and identifying the type of underlying genetic variant is of added value in order to distinguish between pediatric patients with higher risks of premature CVD and to identify those that will benefit most from new types of lipid-lowering therapies. Since in children the phenotype of FH is less affected by environmental factors, the study substantiates the genotype-phenotype correlation in this large pediatric population.
Identifiants
pubmed: 36752612
doi: 10.1097/MOL.0000000000000863
pii: 00041433-202312000-00009
pmc: PMC10624405
doi:
Substances chimiques
Cholesterol, LDL
0
Receptors, LDL
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
287-295Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Circulation. 2020 Jun 2;141(22):1742-1759
pubmed: 32468833
Eur Heart J. 2015 Sep 21;36(36):2425-37
pubmed: 26009596
Nutr Metab (Lond). 2011 Apr 22;8(1):23
pubmed: 21513517
Expert Rev Mol Diagn. 2021 Sep;21(9):887-895
pubmed: 34263698
J Clin Lipidol. 2019 Jul - Aug;13(4):608-617
pubmed: 31255589
N Engl J Med. 2020 Aug 20;383(8):711-720
pubmed: 32813947
Atherosclerosis. 2018 Oct;277:483-492
pubmed: 30270089
Heart. 2018 Oct;104(19):1600-1607
pubmed: 29622598
Annu Rev Genet. 1990;24:133-70
pubmed: 2088165
Lancet Child Adolesc Health. 2021 Sep;5(9):652-661
pubmed: 34119028
Nat Rev Dis Primers. 2017 Dec 07;3:17093
pubmed: 29219151
Eur Heart J. 2022 Sep 7;43(34):3209-3212
pubmed: 35511818
Circulation. 2003 Mar 25;107(11):1473-8
pubmed: 12654602
Eur Heart J. 2014 Aug 21;35(32):2146-57
pubmed: 25053660
Circulation. 2011 Mar 22;123(11):1167-73
pubmed: 21382890
J Pediatr. 2009 Aug;155(2):199-204.e2
pubmed: 19446849
J Pediatr. 2023 Feb;253:18-24.e2
pubmed: 36049522
J Am Coll Cardiol. 2020 May 26;75(20):2553-2566
pubmed: 32439005
Adv Ther. 2022 Apr;39(4):1857-1870
pubmed: 35194765
Am J Cardiol. 2008 Dec 1;102(11):1438-43
pubmed: 19026292
Eur Heart J. 2015 Mar 1;36(9):560-5
pubmed: 24585268
Circulation. 2005 Nov 15;112(20):3168-73
pubmed: 16286607
Eur J Prev Cardiol. 2022 Dec 21;29(18):2301-2311
pubmed: 36059237
Circ Cardiovasc Genet. 2016 Dec;9(6):504-510
pubmed: 27784735